Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
kanakinumab
- Development stage
- Unknown
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Jin na dan kang is a biosimilar version of kanakinumab, a human monoclonal antibody developed by GenSci (Changchun Jinsai Pharmaceutical). It is designed to target and neutralize interleukin-1 beta (IL-1β), a key mediator of inflammation in various autoinflammatory diseases. By binding to IL-1β, the antibody prevents it from interacting with its receptors, thereby blocking the activation of inflammatory pathways. Jin na dan kang is being developed for the treatment of systemic juvenile idiopathic arthritis (sJIA) and gout, and has been evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and immunogenicity in healthy volunteers. The drug is formulated as a lyophilized powder for subcutaneous injection.
- Brand names
- Jin na dan kang
- Other names
- 金纳单抗
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on kanakinumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on kanakinumab.